Trial Information

Immunobiology of Cancer

BACKGROUND

We have previously demonstrated that tumor-specific T cells could be identified in >50% of
patients with metastatic melanoma and these cells appeared to be rendered anergic in vivo
[Nature Medicine 5:677, 1999]. Recently we discovered that there is a signaling defect in
the Interferon (IFN) pathway in immune cells from melanoma patients [PLOS Medicine 4:897
2007]. Interestingly, preliminary studies are showing the same defect in immune cells from
breast cancer patients (unpublished). We would like to expand our research to all types of
cancer to determine whether these phenomena occur in different cancer types.

OBJECTIVES

Our primary objective is to determine whether there is an IFN signaling defect in different
types of cancers and to determine what is causing this defect.

The second objective is to determine whether these PBMCs are rendered anergic.

INVESTIGATIONAL PLAN

The study population will consist of patients who have been diagnosed with cancer,
regardless of sex or ethnicity. Blood will be collected during the subjects regularly
scheduled laboratory appointment and peripheral blood mononuclear cells (PBMCs) will be
isolated for research purposes. These PBMCs will undergo studies, i.e. phosflow, qPCR,
proliferation, survival, etc., to determine immune responses for T cells (CD4 and CD8), B
cells (CD19), natural killer cells (CD16), and possibly monocytes (CD14).